title: Contrast ultrasound targeted treatment of gliomas in mice via drug-bearing nanoparticle delivery and microvascular ablation.
abstract: We are developing minimally-invasive contrast agent microbubble based therapeutic approaches in which the permeabilization and/or ablation of the microvasculature are controlled by varying ultrasound pulsing parameters. Specifically, we are testing whether such approaches may be used to treat malignant brain tumors through drug delivery and microvascular ablation. Preliminary studies have been performed to determine whether targeted drug-bearing nanoparticle delivery can be facilitated by the ultrasound mediated destruction of "composite" delivery agents comprised of 100nm poly(lactide-co-glycolide) (PLAGA) nanoparticles that are adhered to albumin shelled microbubbles. We denote these agents as microbubble-nanoparticle composite agents (MNCAs). When targeted to subcutaneous C6 gliomas with ultrasound, we observed an immediate 4.6-fold increase in nanoparticle delivery in MNCA treated tumors over tumors treated with microbubbles co-administered with nanoparticles and a 8.5 fold increase over non-treated tumors. Furthermore, in many cancer applications, we believe it may be desirable to perform targeted drug delivery in conjunction with ablation of the tumor microcirculation, which will lead to tumor hypoxia and apoptosis. To this end, we have tested the efficacy of non-theramal cavitation-induced microvascular ablation, showing that this approach elicits tumor perfusion reduction, apoptosis, significant growth inhibition, and necrosis. Taken together, these results indicate that our ultrasound-targeted approach has the potential to increase therapeutic efficiency by creating tumor necrosis through microvascular ablation and/or simultaneously enhancing the drug payload in gliomas.
authors.affiliation: Department of Biomedical Engineering, University of Virginia, VA, USA.
authors.forename: Caitlin W
authors.initials: CW
authors.lastname: Burke
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Price
mesh_terms: D000418:Albumins / Q000008:administration & dosage / Q000737:chemistry; D000818:Animals; D001932:Brain Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems / Q000379:methods; D005910:Glioma / Q000098:blood supply / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D045423:Microbubbles / Q000627:therapeutic use; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging / Q000628:therapy; D011098:Polyglactin 910 / Q000008:administration & dosage* / Q000737:chemistry; D051381:Rats; D014463:Ultrasonography
chemical_list: D000418:Albumins; D011098:Polyglactin 910